Program
HRS9432
A development code.
In Jiangsu HengRui Medicine's pipeline, Anidulafungin derivatives
. Its studies are mostly in Candidemia, led by Jiangsu HengRui Medicine.
Furthest: phase 2, since Dec 21, 20231 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 10 open or running | phase 2since Dec 21, 2023 | Dec 21, 2023 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS9432
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 21, 2023First study: phase 2 study in Patients With Candidemia and/or Invasive CandidiasisFirst studyNCT06194201 · 61 enrolled · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Anidulafungin derivatives”the company's pipeline, read by Claude · source
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06194201Patients With Candidemia and/or Invasive Candidiasis · China | 2 | Completed | Nov 7, 2025 | 61 |
How it is read
Names in the registry
- “HRS9432”, 1 entry
Codes read as this program: HRS9432.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.